{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T06:20:15Z","timestamp":1783837215495,"version":"3.55.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T00:00:00Z","timestamp":1261440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:italic>Objective:<\/jats:italic> To determine the clinical significance of changes in quality\u2010of\u2010life scores in patients with multiple myeloma (MM), we have estimated the minimal important difference (MID) for the health\u2010related quality\u2010of\u2010life instrument, the European Organization for Research and Treatment of Cancer (EORTC) QLQ\u2010C30. The MID is the smallest change in a quality\u2010of\u2010life score considered important to patients. <jats:italic>Methods:<\/jats:italic> Between 2006 and 2008, 239 patients with MM completed the EORTC QLQ\u2010C30 at inclusion (T1) and after 3\u2003months (T2). At T2, a structured quality\u2010of\u2010life interview was also performed. MIDs were calculated by using mean score changes (T2\u2013T1) for patients who in the interview stated they had improved, deteriorated or were unchanged. MIDs were also estimated by the receiver\u2010operating characteristic (ROC) curve method as well as by calculation effect sizes using standard deviations of baseline scores. <jats:italic>Results:<\/jats:italic> MIDs varied slightly depending on the method used. Patients stating in the interview that they had \u2018improved\u2019 or \u2018deteriorated\u2019 had a corresponding change in EORTC QLQ\u2010C30 score ranging from 6 to15 (improvement) and from 9 to17 (deterioration) (scale range 0\u2013100). The ROC analysis indicated that changes in score from 7 to17 represent clinically important changes to patients. The effect size method suggested 5\u20136 to be a small and 11\u201315 to be a medium change. <jats:italic>Conclusion:<\/jats:italic> Calculation of MIDs as mean score changes or by ROC analysis suggested that a change in the EORTC QLQ\u2010C30 score in the range of approximately 6\u201317 is considered important by patients with MM. These MIDs are closer to a medium effect size than to a small effect size. Our findings imply that mean score changes smaller than 6 are unlikely to be important to the patients, even if these changes are statistically significant.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2009.01404.x","type":"journal-article","created":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T16:30:08Z","timestamp":1261499408000},"page":"345-353","source":"Crossref","is-referenced-by-count":52,"title":["What changes in health\u2010related quality of life matter to multiple myeloma patients? A prospective study<sup>*<\/sup>"],"prefix":"10.1111","volume":"84","author":[{"given":"Ann K.","family":"Kvam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Wisloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,11]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"111","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"1","author":"Kumar SK","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.065"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.4065\/83.10.1142"},{"key":"e_1_2_8_5_2","first-page":"83","article-title":"Health\u2010related quality of life assessment in randomized controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations","volume":"25","author":"Kvam AK","year":"2009","journal-title":"Eur J Haematol"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00439229"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199915020-00003"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-70"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"e_1_2_8_11_2","first-page":"13","article-title":"The relationship of changes in EORTC QLQ\u2010C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer","volume":"1","author":"Rodrigues G","year":"2004","journal-title":"Qual Life Res"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435226"},{"key":"e_1_2_8_13_2","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen J","year":"1988"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.4065\/77.4.371"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2003.00195.x"},{"key":"e_1_2_8_16_2","first-page":"85","article-title":"The European Organization for Research and Treatment of Cancer QLQ\u2010C30: a quality\u2010of\u2010life instrument for use in international clinical trials in oncology","volume":"3","author":"Aaronson NK","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_8_17_2","volume-title":"The EORTC QLQ\u2010C30 Scoring Manual","author":"Fayers PM","year":"2001"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.352889.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(86)90038-X"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00509.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015276414526"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(03)00044-1"},{"issue":"2","key":"e_1_2_8_23_2","first-page":"4","article-title":"Patient, caregiver, and oncologist perceptions of cancer\u2010related fatigue: results of a tripart assessment survey. The fatigue coalition","volume":"3","author":"Vogelzang NJ","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470024522"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200018050-00001"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C"},{"key":"e_1_2_8_27_2","volume-title":"Clinical Epidemiology: A Basic Science for Clinical Medicine","author":"Sackett DL","year":"1985"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0163278705275340"},{"key":"e_1_2_8_29_2","article-title":"A new approach to combining clinical relevance and statistical significance for evaluation of quality of life changes in the individual patient","author":"Kemmler G","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"e_1_2_8_30_2","article-title":"Three ways to quantify uncertainty in individually applied \u201cminimally important change\u201d values","author":"De Vet HC","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.08202.x"},{"key":"e_1_2_8_32_2","first-page":"32","article-title":"Minimal clinically important change of the Neck Disability Index and the Numerical Rating Scale for patients with neck pain","volume":"15","author":"Pool JJ","year":"2007","journal-title":"Spine (Phila Pa 1976)"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1190"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(99)00047-7"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-7713-0"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2009.01404.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2009.01404.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:32:51Z","timestamp":1697329971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2009.01404.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,11]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1600-0609.2009.01404.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01404.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,11]]}}}